A PHASE I MULTICENTER CLINICAL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF VACCINIA DERIVED HIV-1 RECOMBINANT ENVELOPE GLYCOPROTEIN (GP160) OF HUMAN IMMUNODEFICIENCY VIRUS: EVALUATION OF ACCELERATED SCHEDULES: